Development of ENHERTU, An HER2-directed Dxd ADC, In Early Breast Cancer & Beyond

Time: 8:30 am
day: Day Two


  • Discussing Destiny-Breast03, a Phase 3 randomised study of ENHERTU versus T-DM1 in patients with HER2+ metastatic breast cancer
  • Reviewing plans to develop ENHERTU in early breast cancer
  • Describing plans to expand the development of ENHERTU in gastric cancer, NSCLC and other tumours